At a Glance
- Company: Government of India (Union Finance Ministry)
- Location: India
- Deal value: ₹10,000 crore (≈US$1.1bn) outlay over the scheme period
- Focus area: Biologics and biosimilar R&D, manufacturing, clinical trials
- Next steps: Stand‑up of BioPharma Shakti, build 1,000 trial sites, enable private investment
What happened?
In the Union Budget 2026, Finance Minister Nirmala Sitharaman announced the BioPharma Shakti programme with a total outlay of ₹10,000 crore (around US$1.1 billion). The scheme is designed to accelerate India’s capabilities in biologics and biosimilar R&D, expand clinical‑trial infrastructure and catalyse large‑scale biopharma manufacturing.
Why does it matter?
India has already established itself as a major supplier of small‑molecule generics and vaccines, but scaling into complex biologics and biosimilars requires deeper R&D, quality infrastructure and global‑standard clinical capacity. A ring‑fenced, multi‑year scheme of this size signals long‑term policy commitment and aims to move India up the value chain from volume manufacturer to innovation‑driven biopharma hub.
Who’s behind it?
The programme is led by the central government through the Finance Ministry in coordination with science, health and industry departments, and is expected to be implemented via existing science funding agencies and new mission‑mode vehicles. State governments, academic institutes, hospitals and industry (Indian biopharma companies and multinationals) are likely to be key partners in building and operating new facilities and trial networks.
How was it achieved?
BioPharma Shakti combines targeted public funding with incentives to crowd in private capital, focusing on:
- Support for biologics and biosimilar R&D, including process development and scale‑up.
- Creation of roughly 1,000 new clinical‑trial sites to improve patient access and speed study start‑up.
- Investments in GMP‑compliant biomanufacturing capacity, regulatory‑grade analytics and quality systems.
The scheme builds on earlier production‑linked incentive (PLI) efforts but is tailored to high‑value biologics rather than traditional generics.
What’s next?
Over the coming years, detailed guidelines will define eligibility, funding modalities and priority therapeutic areas such as oncology, autoimmune disease and metabolic disorders. Successful roll‑out would likely include: designation of flagship biopharma clusters, fast‑track regulatory pathways for high‑quality biosimilars, and international partnerships to align with US, EU and other regulators. The government will be looking for measurable increases in late‑stage biologics pipelines, export earnings and India’s share of global clinical trials.
What are people saying?
Industry stakeholders are likely to frame BioPharma Shakti as the biopharma analogue to earlier IT and generic‑drug growth waves, emphasising opportunities to capture complex biologics manufacturing now dominated by a handful of global players. Academic and hospital leaders will focus on the potential to modernise clinical‑research infrastructure and attract more multinational trials to Indian sites.